Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy

Zeina M. Nabhan, Lori K.St Dennis Feezle, Allen Kunselman, Nancy B. Johnson, Peter Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.

Original languageEnglish (US)
Pages (from-to)309-316
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume22
Issue number4
DOIs
StatePublished - Jan 1 2009

Fingerprint

Gonadotropin-Releasing Hormone
Growth
Therapeutics
Central Precocious Puberty
Statistical Factor Analysis
Medical Records

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{7d87f2f7a674418f868888c712dfe2e8,
title = "Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy",
abstract = "Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60{\%} of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.",
author = "Nabhan, {Zeina M.} and Feezle, {Lori K.St Dennis} and Allen Kunselman and Johnson, {Nancy B.} and Peter Lee",
year = "2009",
month = "1",
day = "1",
doi = "10.1515/JPEM.2009.22.4.309",
language = "English (US)",
volume = "22",
pages = "309--316",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. / Nabhan, Zeina M.; Feezle, Lori K.St Dennis; Kunselman, Allen; Johnson, Nancy B.; Lee, Peter.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 22, No. 4, 01.01.2009, p. 309-316.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy

AU - Nabhan, Zeina M.

AU - Feezle, Lori K.St Dennis

AU - Kunselman, Allen

AU - Johnson, Nancy B.

AU - Lee, Peter

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.

AB - Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.

UR - http://www.scopus.com/inward/record.url?scp=67649359979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649359979&partnerID=8YFLogxK

U2 - 10.1515/JPEM.2009.22.4.309

DO - 10.1515/JPEM.2009.22.4.309

M3 - Article

C2 - 19554804

AN - SCOPUS:67649359979

VL - 22

SP - 309

EP - 316

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 4

ER -